TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- B5946 EW-71971 CitationTarget: BMP and Other Activin ReceptorsSummary: Selective inhibitor of TGF-β type I receptor kinase
- B5965 Tamoxifen1 CitationTarget: PKCSummary: TGF-β modulatory and PKC inhibitory effects
- A2600 (-)-Epigallocatechin gallate (EGCG)Target: BACESummary: Antioxidant, antiangiogenic and antitumor agent
- A3133 A 83-01Summary: ALK-5 inhibitor
- B3686 DMH-1Target: BMP and Other Activin ReceptorsSummary: Selective BMP ALK2 receptor
- B3709 Midostaurin (PKC412)Target: PKC|PKA|KDR|Flk1|PPK|c-Syk|CDK1/CyclinBSummary: PKC inhibitor
- B6803 Rottlerin1 CitationTarget: PKC|Ca2 /calmodulin-dependent protein kinases (CaMKs)|PRAK|MAPKAP-K2Summary: PKC inhibitor
- B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor
- B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain
- A3771 RKI-1447Target: ROCKSummary: Potent ROCK1/ROCK2 inhibitor